Myasthenia gravis steroid therapy

Neurologists Dr. Brij Mohan Singh Ahluwalia, MD, Dr. Stephen J. Marks, MD, Dr. Ramandeep Sahni, MD,
Dr. Shyla Kodi, MD, Dr. Robert Fekete, MD, and Dr. Anila Thomas, MD, serving Hawthorne, Valhalla, Scarsdale,
Rye Brook, Tarrytown, Port Chester, Mt. Kisco, Sleepy Hollow, Rye, Harrison, Putnam County, Westchester County, Dutchess County and the surrounding area.
Neurology Associates of Westchester | 19 Bradhurst Avenue | Suite 2850 | Hawthorne, NY 1053 | 914-345-1313

Seven trials involving a total of 199 participants were included. A trial of adrenocorticotrophic hormone (43 participants) did not show any advantage compared with placebo for the treatment of ocular myasthenia gravis. Two double- blind trials compared prednisone with placebo for generalised myasthenia gravis. In the first (13 participants), the improvement was slightly greater in the prednisone group at six months. In the second (20 participants) which was a short-term trial , the improvement was significantly greater at two weeks. Two trials compared glucocorticosteroids with azathioprine (41 and 10 participants respectively). In one of these the rate of treatment failure was greater in the prednisone group. In a trial of glucocorticosteroids versus intravenous immunoglobulin (33 participants) no differences in treatment responses were encountered during a treatment period of 14 days. An open trial (39 participants) evaluating different corticosteroid doses revealed a shorter time to improvement in the high-dose group. None fulfilled the presently accepted standards of a high-quality trial . All these studies have risks of bias and have a weak statistical power .

Myasthenia gravis steroid therapy

myasthenia gravis steroid therapy


myasthenia gravis steroid therapymyasthenia gravis steroid therapymyasthenia gravis steroid therapymyasthenia gravis steroid therapymyasthenia gravis steroid therapy